Co-Authors
This is a "connection" page, showing publications co-authored by CHARLES CLEELAND and QIULING SHI.
Connection Strength
8.138
-
Testing Symptom Severity Thresholds and Potential Alerts for Clinical Intervention in Patients With Cancer Undergoing Chemotherapy. JCO Oncol Pract. 2020 09; 16(9):e893-e901.
Score: 0.725
-
Interpreting Patient-reported Outcome Scores for Clinical Research and Practice: Definition, Determination, and Application of Cutpoints. Med Care. 2019 05; 57 Suppl 5 Suppl 1:S8-S12.
Score: 0.676
-
Determination of mild, moderate, and severe pain interference in patients with cancer. Pain. 2017 06; 158(6):1108-1112.
Score: 0.592
-
Using a symptom-specific instrument to measure patient-reported daily functioning in patients with cancer. Eur J Cancer. 2016 11; 67:83-90.
Score: 0.563
-
Patient-Reported Symptom Interference as a Measure of Postsurgery Functional Recovery in Lung Cancer. J Pain Symptom Manage. 2016 12; 52(6):822-831.
Score: 0.560
-
Racial/ethnic disparities in inflammatory gene single-nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis. Cancer. 2015 Apr 01; 121(7):1138-46.
Score: 0.498
-
Using group-based trajectory modeling to examine heterogeneity of symptom burden in patients with head and neck cancer undergoing aggressive non-surgical therapy. Qual Life Res. 2013 Nov; 22(9):2331-9.
Score: 0.442
-
Anastrozole-associated joint pain and other symptoms in patients with breast cancer. J Pain. 2013 Mar; 14(3):290-6.
Score: 0.441
-
Symptom burden in cancer survivors 1 year after diagnosis: a report from the American Cancer Society's Studies of Cancer Survivors. Cancer. 2011 Jun 15; 117(12):2779-90.
Score: 0.387
-
Does recall period have an effect on cancer patients' ratings of the severity of multiple symptoms? J Pain Symptom Manage. 2010 Aug; 40(2):191-9.
Score: 0.366
-
Assessing persistent cancer pain: a comparison of current pain ratings and pain recalled from the past week. J Pain Symptom Manage. 2009 Feb; 37(2):168-74.
Score: 0.321
-
People in pain: how do they seek relief? J Pain. 2007 Aug; 8(8):624-36.
Score: 0.297
-
Minocycline for symptom reduction in patients with multiple myeloma during maintenance therapy: a phase II placebo-controlled randomized trial. Support Care Cancer. 2021 Oct; 29(10):6099-6107.
Score: 0.193
-
The Treatment-induced Neuropathy Assessment Scale (TNAS): a psychometric update following qualitative enrichment. J Patient Rep Outcomes. 2020 Feb 19; 4(1):15.
Score: 0.179
-
Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial. Support Care Cancer. 2020 Jan; 28(1):261-269.
Score: 0.169
-
Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer. Oncology. 2016; 90(3):127-35.
Score: 0.135
-
Measuring Therapy-Induced Peripheral Neuropathy: Preliminary Development and Validation of the Treatment-Induced Neuropathy Assessment Scale. J Pain. 2015 Oct; 16(10):1032-43.
Score: 0.130
-
Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation. Clin Cancer Res. 2014 Mar 01; 20(5):1366-74.
Score: 0.117
-
Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy. Brain Behav Immun. 2012 Jul; 26(5):699-705.
Score: 0.102
-
Automated symptom alerts reduce postoperative symptom severity after cancer surgery: a randomized controlled clinical trial. J Clin Oncol. 2011 Mar 10; 29(8):994-1000.
Score: 0.095
-
Biological pathways and genetic variables involved in pain. Qual Life Res. 2010 Dec; 19(10):1407-17.
Score: 0.093
-
Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancer. Cancer. 2010 Jan 01; 116(1):137-45.
Score: 0.089
-
Trajectory, interactions, and predictors of higher symptom burden during induction therapy for multiple myeloma. J Patient Rep Outcomes. 2024 Dec 04; 8(1):141.
Score: 0.062
-
Patient-reported outcomes after oncologic hepatic resection predict the risk of delayed readiness to return to intended oncologic therapy (RIOT). Eur J Surg Oncol. 2024 Jul; 50(7):108396.
Score: 0.060
-
Utility of Patient-Reported Symptom and Functional Outcomes to Indicate Recovery after First 90 Days of Radical Cystectomy: A Longitudinal Study. Cancers (Basel). 2023 Jun 04; 15(11).
Score: 0.056
-
Patient-reported symptoms at discharge and risk of complications after gynecologic surgery. Int J Gynecol Cancer. 2023 02 06; 33(2):271-277.
Score: 0.055
-
Development of a patient-reported outcome tool for assessing symptom burden during perioperative care in liver surgery: The MDASI-PeriOp-Hep. Eur J Oncol Nurs. 2021 Jun; 52:101959.
Score: 0.049
-
Assessment of physical function by subjective and objective methods in patients undergoing open gynecologic surgery. Gynecol Oncol. 2021 04; 161(1):83-88.
Score: 0.048
-
What Do Patients With Non-Small-Cell Lung Cancer Experience? Content Domain for the MD Anderson Symptom Inventory for Lung Cancer. JCO Oncol Pract. 2020 10; 16(10):e1151-e1160.
Score: 0.046
-
Symptom burden and its functional impact in patients with "symptomatic" relapsed or refractory multiple myeloma. Support Care Cancer. 2021 Jan; 29(1):467-475.
Score: 0.045
-
A Randomized, Placebo-Controlled, Double-Blind Study of Minocycline for Reducing the Symptom Burden Experienced by Patients With Advanced Pancreatic Cancer. J Pain Symptom Manage. 2020 05; 59(5):1052-1058.e1.
Score: 0.044
-
Minocycline Reduces Chemoradiation-Related Symptom Burden in Patients with Non-Small Cell Lung Cancer: A Phase 2 Randomized Trial. Int J Radiat Oncol Biol Phys. 2020 01 01; 106(1):100-107.
Score: 0.044
-
Minocycline for Symptom Reduction During Oxaliplatin-Based Chemotherapy for Colorectal Cancer: A Phase II Randomized Clinical Trial. J Pain Symptom Manage. 2019 10; 58(4):662-671.
Score: 0.043
-
Validation and application of a module of the MD Anderson Symptom Inventory for measuring perioperative symptom burden in patients with gynecologic cancer (the MDASI-PeriOp-GYN). Gynecol Oncol. 2019 03; 152(3):492-500.
Score: 0.042
-
Assessment of baseline symptom burden in treatment-na?ve patients with lung cancer: an observational study. Support Care Cancer. 2019 Sep; 27(9):3439-3447.
Score: 0.041
-
A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors. Cancer Med. 2018 11; 7(11):5457-5469.
Score: 0.041
-
Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation: an observational study. Qual Life Res. 2018 06; 27(6):1563-1570.
Score: 0.039
-
Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes. Int J Radiat Oncol Biol Phys. 2016 07 15; 95(4):1107-14.
Score: 0.034
-
Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy. J Pain Symptom Manage. 2016 05; 51(5):832-8.
Score: 0.034
-
Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis. Biol Blood Marrow Transplant. 2016 Feb; 22(2):226-231.
Score: 0.033
-
Symptom recovery after thoracic surgery: Measuring patient-reported outcomes with the MD Anderson Symptom Inventory. J Thorac Cardiovasc Surg. 2015 Sep; 150(3):613-9.e2.
Score: 0.032
-
Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma. Leuk Lymphoma. 2015 May; 56(5):1335-41.
Score: 0.031
-
Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 data. Expert Rev Pharmacoecon Outcomes Res. 2011 Oct; 11(5):587-99.
Score: 0.025
-
Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain Behav Immun. 2010 Aug; 24(6):968-74.
Score: 0.023
-
The establishment of the GENEQOL consortium to investigate the genetic disposition of patient-reported quality-of-life outcomes. Twin Res Hum Genet. 2009 Jun; 12(3):301-11.
Score: 0.021
-
Serum interleukin-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation. Cancer. 2008 Oct 15; 113(8):2102-9.
Score: 0.020